医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

EnzymeWorks, Inc. and Codexis, Inc. Reach a Settlement Agreement

2018年02月06日 AM05:57
このエントリーをはてなブックマークに追加


 

SUZHOU, China

After nearly two years of litigation, EnzymeWorks, Inc. and Codexis, Inc. have decided to reach a settlement agreement.

All claims against EnzymeWorks’ founder Alex Tao have been dismissed with prejudice. Claims against EnzymeWorks including trade secret misappropriation and breach of contract have been dismissed with prejudice. As for patent infringement, both parties have stipulated to a judgment. For details please see https://www.businesswire.com/news/home/20170811005520/en/EnzymeWorks-Dr.-Alex-Tao-Respond-Press-Release. Biocatalysis is a relatively new field, and some guidelines are coming up to minimize legal risks and make the technology more attractive for chemical production. Learn more at http://www.enzymeworking.com/index.php?_m=mod_article&_a=article_content&article_id=260.

We greatly appreciate our friends and customers’ trust and support during those difficult times, and especially thank our legal counsel J. James Li and his team at LiLaw Inc. for their professional services, deep experience and dedication.

With the case behind, EnzymeWorks and Alex Tao will continue to improve the biocatalysis technology making it more efficient for green chemical manufacturing. EnzymeWorks develops its own enzymes and processes via retrosynthetic integration with chemical transformations, and is always committed to taking responsibility for IP.

About EnzymeWorks, Inc: EnzymeWorks is a world leader in applying biosynthesis and green chemistry as its core technologies for CROs and CMOs. The company has developed more classes of biocatalysts than any other companies, and also supplies many cofactors including NAD, NADP, UDP-sugars, PLP etc. at large scale. It has also the largest enzyme and fermentation facility including DSP and freeze drying. Its research team has contributed to over 20 books, filed over 100 patents and received numerous honors and awards in biocatalysis and green chemistry. Learn more at www.enzymeworking.com.

About LiLaw Inc: LiLaw Inc. is a dynamic intellectual property, business litigation and employment law firm based in California, USA. Its founder, attorney J. James Li, is a seasoned trial lawyer listed in the National Register’s Who’s Who in Executives and Professionals with nearly 20 years of experiences in various business legal matters. His vision is to provide high quality and yet affordable legal services to small and midsize companies. Learn more at www.lilaw.us.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180205005939/en/

CONTACT

Press Contact:
EnzymeWorks, Inc.
Ling Zhu
+86 512
8883 8789
services@enzymeworking.com

同じカテゴリーの記事 

  • AtriCure已就在中国销售AtriClip®器械获得监管批准
  • ベイジーン、米国に生物製剤製造および臨床研究開発の旗艦施設を開設し、世界のより多くの患者に医薬品を届けるためのグローバルな拡大を継続
  • KBIバイオファーマがFDA検閲を通過、世界的な大手製薬会社との商業契約を延長・拡大
  • 继成功通过FDA检查后,KBI Biopharma续签并扩大了与全球领先制药公司的商业合同
  • BCF, BREF and TBG Companies Seek Global Financial Support to Establish 1000s of Best Cure Pro Health and Medical Centers